Sharemaestro Newsreel

ANI Pharmaceuticals Inc (ANIP) Institutional Confidence

ANI Pharmaceuticals Inc (ANIP) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 101.74%, showing a 1.25% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.87% of shares outstanding.

KMDA Q1 2026 Earnings: EPS Misses Estimates but Stock Holds on Positive Ground - Pre-Earnings Drift

LFCR Q1 2026 Earnings: Significant Earnings Miss Amid Operational Challenges - Pretax Income Report

Regencell Bioscience (RGC) Dips Slightly, Testing Key Support Near $5.62 - Dividend ETF

Caring Brands Inc. (CABR) Rallies 4%—Bulls Test Key Resistance at $1.64 - Regression Channel

Bausch Health (NYSE: BHC) boosts 2026 guidance on strong Q2 2026 results

Biofrontera Inc. (BFRI) Q1 2026 Earnings: EPS Misses Estimates Sharply Despite Share Gain - High Growth Earnings

INCR Q2 2023 Earnings: EPS Surprises to the Upside Despite Stock Decline - Adjusted Earnings Analysis

KMDA Q1 2026 Earnings: EPS Misses Estimates as Stock Declines - Consensus Forecast Report

Renaissance Technologies LLC Acquires 31,435 Shares of Phibro Animal Health Corporation $PAHC

Lantheus (LNTH) to Release Earnings on Wednesday

HC Wainwright Analysts Decrease Earnings Estimates for CRDL

Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Evolus (EOLS) Projected to Post Quarterly Earnings on Wednesday

Cumberland Pharmaceuticals (CPIX.US) will release its earnings report after the market closes on August 4.

Perrigo (PRGO) Projected to Release Quarterly Earnings on Wednesday

Emergent Biosolutions (EBS) Projected to Post Earnings on Wednesday

Anika Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ANIK) 2026-07-29

Aurora Cannabis (ACB) to Post Quarterly Earnings on Wednesday

Phibro Animal Health Corporation (NASDAQ:PAHC) Announces $0.12 Quarterly Dividend

BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday

Wedbush Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $98.00

Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1

Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD

Amneal Pharmaceuticals stock (AMRX) recently hit a 52-week high of $18.59, reflecting a 123.61% increase over the past year. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued. The company also reported strong Q1 2026 results and received FDA approvals for …

Tilray Brands, Inc. Stock 12‑Month Price Target Cut to $8.52, Implies 111% Upside

Tilray Brands, Inc.'s average 12-month price target has been cut to $8.52 from $8.62, according to estimates from 6 analysts. This updated target implies a potential upside of approximately 111% from its July 28 closing price. The consensus rating for TLRY remains "Buy," with …

Indivior PLC (INDV) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Indivior PLC (INDV), highlighting its current risk score of 6.43, ranking 53 out of 155 in the Pharmaceuticals industry. The company's beta of 1.18 suggests it tends to outperform during market uptrends but underperform during downtrends. The …

Bausch Health Companies Inc (BHC) Valuation: PE, PB & Fair Value Analysis

Bausch Health Companies Inc (BHC) has a current valuation score of 9.34, ranking 27th out of 155 companies in the Pharmaceuticals industry. The company's P/E ratio is -1.40, which is significantly below its recent high and above its recent low. However, relevant data for …

TherapeuticsMD, Inc. Revenue Breakdown – SWB:29TA

This article provides a revenue breakdown for TherapeuticsMD, Inc. (SWB:29TA), highlighting that the greatest contribution to its revenue comes from the United States. The company reported €1.53 million from the U.S. last year, an increase from €1.08 million the year prior. The data is …

Supernus Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Supernus Pharmaceuticals (NASDAQ: SUPN) had 793 employees as of March 2026, representing a 25.8% decline from 2023. The company is actively hiring, with 105 job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, …

ANI Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

ANI Pharmaceuticals (NASDAQ: ANIP) has approximately 1,030 employees worldwide as of March 2026, marking a 17.1% growth since 2023. The company is actively hiring, with 60 job postings in 2026, and its workforce is primarily concentrated in North America, with an average salary of …

Evotec SE (EVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Evotec SE (EVO), focusing on its current price momentum, support and resistance levels, and key indicators like MACD, RSI, and Moving Averages. The stock's price momentum score is 5.21, and it is trading between a resistance of …

Tilray Brands 4Q Loss/Shr 43c >TLRY

Tilray Brands reported a fourth-quarter loss per share of 43 cents. This financial update indicates the company's performance for the recent quarter.

Tilray Brands Inc reports results for the quarter ended May 31 - Earnings Summary

Tilray Brands Inc has released its earnings summary for the quarter that concluded on May 31. The report contains the financial results for the company during this period. The full article provides detailed information on their performance.

Sonoma Pharmaceuticals (Nasdaq: SNOA) 2026 pay, board and auditor votes

Sonoma Pharmaceuticals (SNOA) has issued its definitive proxy statement for the 2026 Annual Meeting, scheduled for September 16, 2026. Shareholders will vote on the re-election of Class III director Jerry McLaughlin, an advisory approval of executive compensation for fiscal year 2026, and the ratification …

Dr. Reddy’s Laboratories (NYSE: RDY) details Q1 impact from semaglutide

Dr. Reddy's Laboratories reported a 5.6% year-on-year decline in Q1 FY27 consolidated revenues, totaling ₹8,071 crores, primarily due to lower lenalidomide sales and a ₹240 crore provision for semaglutide API issues. Despite this, the base business, excluding lenalidomide, showed healthy double-digit growth across key …